Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more
Xlife Sciences AG (XLS) - Net Assets
Latest net assets as of June 2025: CHF303.42 Million CHF
Based on the latest financial reports, Xlife Sciences AG (XLS) has net assets worth CHF303.42 Million CHF as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF536.26 Million) and total liabilities (CHF232.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF303.42 Million |
| % of Total Assets | 56.58% |
| Annual Growth Rate | 25.66% |
| 5-Year Change | 134.51% |
| 10-Year Change | N/A |
| Growth Volatility | 19.37 |
Xlife Sciences AG - Net Assets Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xlife Sciences AG (2019–2024)
The table below shows the annual net assets of Xlife Sciences AG from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF305.26 Million | +13.83% |
| 2023-12-31 | CHF268.17 Million | +14.00% |
| 2022-12-31 | CHF235.23 Million | +11.36% |
| 2021-12-31 | CHF211.23 Million | +62.28% |
| 2020-12-31 | CHF130.17 Million | +33.68% |
| 2019-12-31 | CHF97.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xlife Sciences AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 207.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF287.67 Million | 94.24% |
| Common Stock | CHF5.74 Million | 1.88% |
| Other Components | CHF11.85 Million | 3.88% |
| Total Equity | CHF305.26 Million | 100.00% |
Xlife Sciences AG Competitors by Market Cap
The table below lists competitors of Xlife Sciences AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CBAK Energy Technology Inc
NASDAQ:CBAT
|
$70.33 Million |
|
AFFINITY BANCSHS DL-01
F:5610
|
$70.38 Million |
|
Digital Daesung Co. Ltd
KQ:068930
|
$70.39 Million |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
$70.40 Million |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
$70.32 Million |
|
Tempo Scan Pacific Tbk
JK:TSPC
|
$70.32 Million |
|
Eucatex S.A. Indústria e Comércio
SA:EUCA3
|
$70.28 Million |
|
Anadolu Isuzu Otomotiv Sanayi ve Ticaret AS
IS:ASUZU
|
$70.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xlife Sciences AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 268,173,270 to 305,260,120, a change of 37,086,850 (13.8%).
- Net income of 34,276,840 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF34.28 Million | +11.23% |
| Other Changes | CHF2.81 Million | +0.92% |
| Total Change | CHF- | 13.83% |
Book Value vs Market Value Analysis
This analysis compares Xlife Sciences AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.42x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.86x to 0.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CHF25.89 | CHF22.30 | x |
| 2020-12-31 | CHF31.31 | CHF22.30 | x |
| 2021-12-31 | CHF41.75 | CHF22.30 | x |
| 2022-12-31 | CHF44.52 | CHF22.30 | x |
| 2023-12-31 | CHF47.95 | CHF22.30 | x |
| 2024-12-31 | CHF53.16 | CHF22.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xlife Sciences AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.23%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4105.60%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.77x
- Recent ROE (11.23%) is above the historical average (10.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 1.08% | 203.99% | 0.00x | 1.58x | CHF-8.69 Million |
| 2020 | 16.49% | 5408.40% | 0.00x | 1.43x | CHF8.44 Million |
| 2021 | 25.29% | 6627.03% | 0.00x | 2.27x | CHF32.30 Million |
| 2022 | 6.08% | 1392.26% | 0.00x | 2.08x | CHF-9.21 Million |
| 2023 | 5.55% | 1505.33% | 0.00x | 1.91x | CHF-11.94 Million |
| 2024 | 11.23% | 4105.60% | 0.00x | 1.77x | CHF3.75 Million |
Industry Comparison
This section compares Xlife Sciences AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $661,479,607
- Average return on equity (ROE) among peers: -284.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xlife Sciences AG (XLS) | CHF303.42 Million | 1.08% | 0.77x | $70.33 Million |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $495.17K |
| Newron Pharmaceuticals SpA (NWRN) | $67.72 Million | -7.80% | 0.08x | $317.49 Million |
| Spexis AG (SPEX) | $2.29 Million | -857.53% | 6.33x | $4.21 Million |